Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Net Cash Flow: 2020-2025

Historic Net Cash Flow for Foghorn Therapeutics (FHTX) over the last 6 years, with Sep 2025 value amounting to $16.8 million.

  • Foghorn Therapeutics' Net Cash Flow rose 120.63% to $16.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.2 million, marking a year-over-year increase of 362.89%. This contributed to the annual value of -$24.9 million for FY2024, which is 188.48% down from last year.
  • Per Foghorn Therapeutics' latest filing, its Net Cash Flow stood at $16.8 million for Q3 2025, which was up 28.07% from $13.1 million recorded in Q2 2025.
  • In the past 5 years, Foghorn Therapeutics' Net Cash Flow ranged from a high of $112.5 million in Q1 2022 and a low of -$152.4 million during Q2 2022.
  • In the last 3 years, Foghorn Therapeutics' Net Cash Flow had a median value of $7.1 million in 2023 and averaged $3.5 million.
  • Over the last 5 years, Foghorn Therapeutics' Net Cash Flow had its largest YoY gain of 745.28% in 2024, and its largest YoY loss of 744.84% in 2024.
  • Foghorn Therapeutics' Net Cash Flow (Quarterly) stood at $43.3 million in 2021, then plummeted by 181.80% to -$35.4 million in 2022, then skyrocketed by 128.32% to $10.0 million in 2023, then plummeted by 122.17% to -$2.2 million in 2024, then spiked by 120.63% to $16.8 million in 2025.
  • Its Net Cash Flow stands at $16.8 million for Q3 2025, versus $13.1 million for Q2 2025 and $5.6 million for Q1 2025.